Cantor Fitzgerald Reaffirms Their Hold Rating on Merck & Company (MRK)
Cantor Fitzgerald analyst Carter Gould maintained a Hold rating on Merck & Company yesterday and set a price target of $120.00.
End of Quarter Sale - 50% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Gould covers the Healthcare sector, focusing on stocks such as Merck & Company, Gilead Sciences, and Pfizer. According to TipRanks, Gould has an average return of 5.9% and a 51.76% success rate on recommended stocks.
In addition to Cantor Fitzgerald, Merck & Company also received a Hold from Morgan Stanley’s Terence Flynn in a report issued today. However, on the same day, Barclays maintained a Buy rating on Merck & Company (NYSE: MRK).
Based on Merck & Company’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $16.4 billion and a net profit of $2.96 billion. In comparison, last year the company earned a revenue of $15.62 billion and had a net profit of $3.74 billion
Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MRK in relation to earlier this year. Last month, Chirfi Guindo, the CMO of MRK sold 10,000.00 shares for a total of $1,214,500.00.
Read More on MRK:
Disclaimer & DisclosureReport an Issue
- Winrevair’s Mixed Phase 2 Signal Leaves Merck’s Risk‑Reward Balanced, Supporting a Hold Rating
- Merck announces data from Phase 2 Cadence trial of Winrevair
- Wix downgraded, TripAdvisor upgraded: Wall Street’s top analyst calls
- Terns Pharmaceuticals downgraded to Market Perform from Outperform at BMO Capital
- Agilent receives FDA approval for PD-L1 1HC 22C3 pharmDx
